Use of long‐acting cabotegravir and rilpivirine in people living with HIV : A prospective observational cohort study
HIV Medicine · 2026-07 · 27 (7) · 1075-1083
DOI: 10.1111/hiv.70230 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift HIV Medicine, online erschienen am 26.03.2026. Verfasst von Ana Codonal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Hospital Santos Reyes, Aranda de Duero, Spain. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, Pyridones, Anti-HIV Agents. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objectives
Cabotegravir and rilpivirine long‐acting (CAB+RPV LA) is a novel switch strategy for people living with HIV. Our aim was to identify factors associated with therapeutic failure (TF) and virological failure (VF).
Methods
We conducted a single‐centre prospective cohort study. We reviewed all people living with HIV who initiated CAB+RPV LA between 14 February 2023 and 6 May 2025 in the hospital. Reasons for treatment discontinuation (VF, toxicity, poor adherence, death, pregnancy, transfer to another centre or oral bridging) were analysed, as well as virological effectiveness and the emergence of resistance mutations. Safety, adherence and overall regimen durability were also evaluated. The proportion of patients with HIV‐RNA < 50 copies/mL at months 1, 7 and 13 was analysed using intention‐to‐treat (ITT) and on‐treatment (OT) approaches.
Results
CAB+RPV LA was administered to 35% of the hospital's cohort (151/429). Of the 151 patients, 80% were male, with a median age of 40 years. A total of 116 patients reached 13 months of treatment. After a median follow‐up of 18.8 months (interquartile range [IQR]: 11–23.7), 28 (18.5%) patients discontinued treatment, 3 (2%) of them due to VF (one with resistance mutations to both rilpivirine and cabotegravir). The proportions of patients with HIV‐RNA < 50 copies/mL at months 1, 7 and 13 were 96%, 91% and 85% (ITT) and 96%, 95% and 93% (OT), respectively. Reasons for discontinuation included VF (2%), adverse events (4%), poor adherence (3%), transfer to another hospital (5%), oral bridging (4%) and difficulty attending appointments (1%). The modified therapeutic failure rate (excluding oral bridging and transfers) was 7.42 (95% confidence interval [CI]: 4.3–12.0) per 100 person‐years.
Conclusions
CAB+RPV LA appears to be an effective, safe and durable option for a switch strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Hospital Santos Reyes, Aranda de Duero, Spain.
- University of Alcalá, Alcalá de Henares, Spain.
- Pharmacy Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.
- Internal Medicine Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.
- Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Castilla-La Mancha, Spain.
ORCID-Profile: Ana Codonal, Miguel Torralba
Zitieren
APA
Codonal, A., Lázaro, A., Martínez, E., Delgado, A., & Torralba, M. (2026). Use of long‐acting cabotegravir and rilpivirine in people living with HIV : A prospective observational cohort study. HIV Medicine, 27(7), 1075-1083. https://doi.org/10.1111/hiv.70230
Vancouver
Codonal A, Lázaro A, Martínez E, Delgado A, Torralba M. Use of long‐acting cabotegravir and rilpivirine in people living with HIV : A prospective observational cohort study. HIV Medicine. 2026;27(7):1075-1083. doi:10.1111/hiv.70230
BibTeX
@article{Codonal2026,
author = {Codonal, Ana and Lázaro, Alicia and Martínez, Elena and Delgado, Alberto and Torralba, Miguel},
title = {Use of long‐acting cabotegravir and rilpivirine in people living with HIV : A prospective observational cohort study},
journal = {HIV Medicine},
year = {2026},
volume = {27},
number = {7},
pages = {1075--1083},
doi = {10.1111/hiv.70230}
}
EUVIMED